TABLE 2.

Associations of MCTS1 expression with clinicopathological characteristics of patients (n = 1,065).

Characteristics	Total (N)	Odds ratio (OR)	p value
T stage (T3&T4 vs. T1&T2)	1,062	1.244 (0.897–1.729)	0.192
N stage (N1&N2&N3 vs. N0)	1,046	1.104 (0.866–1.408)	0.423
M stage (M1 vs. M0)	909	3.048 (1.170–9.435)	0.032
Pathologic stage (Stage III &Stage IV vs. Stage I &Stage II)	1,042	1.042 (0.786–1.382)	0.773
Age (>60 vs. ≤60)	1,065	1.281 (1.006–1.632)	0.045
Race (White vs. Asian &Black or African American)	976	0.667 (0.496–0.894)	0.007
ER status (Positive vs. Negative)	1,015	0.983 (0.735–1.315)	0.907
PR status (Positive vs. Negative)	1,012	1.181 (0.909–1.534)	0.214
HER2 status (Positive vs. Negative)	705	1.402 (0.983–2.006)	0.063
PAM50 (Luminal B&Her2&Basal vs. Luminal A)	1,025	1.463 (1.143–1.874)	0.003
Menopause status (Post vs. Pre &Peri)	956	1.271 (0.956–1.691)	0.099
Anatomic neoplasm subdivisions (Right vs. Left)	1,065	0.870 (0.684–1.107)	0.257
Radiation therapy (Yes vs. No)	972	1.079 (0.838–1.390)	0.556
Histological type (Infiltrating Lobular Carcinoma vs. Infiltrating Ductal Carcinoma)	959	0.439 (0.317–0.605)	<0.001

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Bold values denote two-sided p < 0.05.